This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
A pharmaceutical company was alleged to have misrepresented (false advertising) the medical and health benefits of over-the-counter multivitamin products and doing economic harm to consumers that purchased those products. The claimants sought to certify a class for affected consumers and initiate a class action complaint to recover class wide economic damages.
Intensity was retained to determine an appropriate methodology for certifying the consumer class, and to perform economic analysis related to price premiums on products that were advertised with certain false claims. Intensity evaluated various methodologies for certifying the consumer class and proposed a methodology that was appropriate based on product sales data and consumer demographics.
Intensity also performed an analysis of damages relating to a class action complaint of unfair competition, violation of Consumer’s Legal Remedies Act, and false advertising relating to health products. Intensity estimated damages incurred based on an analysis of the economic effects of the alleged conduct on product sales and profitability.
Economic issues included class certification, price premiums, common class-wide impact, unfair competition, false advertising, and treble damages.
Statistics Tools Chart A Path For AI Use In Expert Testimony
As AI and machine learning tools become more common in expert workflows, courts are increasingly scrutinizing their use under Federal Rule of Evidence 702. In The Risks and a Path Forward for AI and Machine Learning Tools in Expert Testimony, we examine recent cases where AI-assisted opinions were excluded due to concerns about reliability, transparency, and expert understanding.
In this GIR article, Stephen Millington and Dominique Dondelinger examine the growing fraud risks facing the Gulf region amid rapid economic expansion and transformative Vision 2030 strategies.
Public Cos. Must Heed Disclosure Risks Amid Trade Chaos
Ongoing uncertainties caused by the trade war and President Donald Trump’s evolving stance on tariffs and trade restrictions, including sanctions and export controls, have exponentially escalated financial reporting pressures on public companies. In this article, we discuss the key financial reporting and disclosure risks, as well as takeaways, for public companies as they navigate significant market instability in international trade.